US NDA submitted for Brilinta

RNS Number : 7369C

AstraZeneca PLC

19 November 2009

 



ASTRAZENECA SUBMITS US NEW DRUG APPLICATION FOR BRILINTA (TICAGRELOR), AN INVESTIGATIONAL ANTIPLATELET AGENT

AstraZeneca today announced it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS). The proposed trade name for ticagrelor is BRILINTA, pending approval from the FDA.

This submission is based on the results of a comprehensive programme, including data from PLATO (A Study of Platelet Inhibition and Patient Outcomes), the Phase III head-to-head trial comparing ticagrelor plus aspirin with clopidogrel (Plavix®) plus aspirin. 

Acute coronary syndrome (ACS) is an umbrella term for conditions that result from a reduction in blood flow to the heart muscle.  These conditions range from unstable angina (chest pain) to myocardial infarction (heart attack).  According to the American Heart Association, ACS affects an estimated 1.4 million people in the US every year. It is estimated that one in three ACS patients will die, have another heart attack or be hospitalised again within six months of the first cardiovascular event. 

Ticagrelor is the first reversibly binding oral P2Y12 adenosine diphosphate (ADP) receptor antagonist. ADP receptor antagonists inhibit the action of platelets in the blood to prevent platelets from sticking together, thereby reducing recurrent thrombotic events. 

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information about AstraZeneca, please visit: www.astrazeneca.com

Media Enquiries UK:
Chris Sampson	[phone] (24 hours)
Neil McCrae	[phone] (24 hours)
Sarah Lindgreen	[phone] (24 hours)
Abigail Baron	[phone] (24 hours)
Investor Enquiries UK:
Jonathan Hunt	[phone]	mob: [phone]
Karl Hard	[phone]	mob: [phone]
Clive Morris	[phone]	mob: [phone]
Investor Enquiries US:
Ed Seage	[phone]	mob: [phone]
Jorgen Winroth	[phone]	mob: [phone]

19 November 2009

- ENDS -

 

END

 

 

MSCILFLTLALTLIA